不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性
|
摘要
目的探讨不同化疗方案治疗晚期非小细胞肺癌(non small cell lung cancer,NSCLC)的临床疗效及肿瘤标志物与疗效的相关性。方法选取2015-01至2017-06北京大学首钢医院收治的96例晚期NSCLC患者为研究对象,随机分为吉西他滨+顺铂组(GP组)和培美曲赛+顺铂组(AP组),每组48例,GP组给予吉西他滨+顺铂化疗,AP组给予培美曲赛+顺铂化疗。比较两组患者化疗疗效及肿瘤标志物的变化情况。结果两组患者化疗后,AP组ORR(29.17%)和DCR(81.25%)均显著高于GP组,比较差异均有统计学意义(P<0.05)。化疗后,GP组与AP组的癌胚抗原水平分别为54.6±7.9、23.5±5.9,CA125分别为87.8±7.2、50.4±8.3。治疗前两组CEA和CA125水平相比差异无有统计学意义,治疗后两组CEA和CA125水平均较治疗前显著下降(P<0.05),治疗后AP组各指标下降程度大于GP组,差异有统计学意义(P<0.05)。结论给予晚期NSCLC患者AP方案化疗能显著提高临床疗效,且明显降低患者肿瘤标志物的水平,值得推广。
Objective To investigate the clinical efficacy of different chemotherapy regimens in the treatment of advanced nonsmall cell lung cancer and the correlations between tumor markers and clinical efficacy. Methods Ninety-six cases of advanced nonsmall cell lung cancer patients admitted between January 2015 and June 2017 were selected as subjects. They were randomly divided into GP and AP group. GP group was given gemcitabine plus cisplatin chemotherapy,while AP group was given permedusa plus cisplatin chemotherapy. Chemotherapy efficacy and tumor markers were compared between the two groups. Results After chemotherapy,the ORR( 29. 17%) and DCR( 81. 25%) in the AP group were significantly higher than those in the GP group( P < 0. 05). After chemotherapy,the level of cancer embryo antigens in the GP group and AP group was 54. 6 ± 7. 9 and 23. 5 ± 5. 9 respectively,while CA125 was 87. 8 ± 7. 2 and 50. 4 ± 8. 3 respectively. Before treatment,CEA and CA125 levels of the two groups were not statistically significant,but were significantly different after treatment( P < 0. 05). After treatment,the index of the AP group was decreased more significantly than in GP group,and the difference was statistically significant( P < 0. 05). Conclusions AP chemotherapy can significantly improve the clinical efficacy of patients with advanced non-small cell lung cancer,and reduce the level of tumor markers. It is worth promoting.
Objective To investigate the clinical efficacy of different chemotherapy regimens in the treatment of advanced nonsmall cell lung cancer and the correlations between tumor markers and clinical efficacy. Methods Ninety-six cases of advanced nonsmall cell lung cancer patients admitted between January 2015 and June 2017 were selected as subjects. They were randomly divided into GP and AP group. GP group was given gemcitabine plus cisplatin chemotherapy,while AP group was given permedusa plus cisplatin chemotherapy. Chemotherapy efficacy and tumor markers were compared between the two groups. Results After chemotherapy,the ORR( 29. 17%) and DCR( 81. 25%) in the AP group were significantly higher than those in the GP group( P < 0. 05). After chemotherapy,the level of cancer embryo antigens in the GP group and AP group was 54. 6 ± 7. 9 and 23. 5 ± 5. 9 respectively,while CA125 was 87. 8 ± 7. 2 and 50. 4 ± 8. 3 respectively. Before treatment,CEA and CA125 levels of the two groups were not statistically significant,but were significantly different after treatment( P < 0. 05). After treatment,the index of the AP group was decreased more significantly than in GP group,and the difference was statistically significant( P < 0. 05). Conclusions AP chemotherapy can significantly improve the clinical efficacy of patients with advanced non-small cell lung cancer,and reduce the level of tumor markers. It is worth promoting.
引文
[1]卢晓艳.不同化疗方案对晚期非小细胞肺癌临床疗效及肿瘤标志物的影响[J].吉林医学,2016,37(12):2938-2939.
[2]冯高华,陈晓峰.不同化疗方案治疗晚期非小细胞肺癌的疗效及对肿瘤标志物水平的影响[J].中国老年学杂志,2014,34(23):6601-6603.
[3]赵玉霞.吉西他滨联合顺铂对IIIB或IV期非小细胞肺癌的治疗效果[J].中国实用医刊,2017,44(1):87-88.
[4]太祥,陈满军,洪文娟,等.培美曲塞和紫杉醇分别联合奥沙利铂用于非小细胞肺癌术后辅助化学治疗疗效比较[J].重庆医学,2015,44(35):4936-4939.
[5]Bai M S,Wang X C,Luo L,et al.Clinical Efficacy of Aidi Injection Combined with DP Chemotherapy Regimen for Female Advanced Lung Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2016.
[6]李妮,邓泽虎,田福华,等.放射性125I粒子植入联合紫杉醇治疗非小细胞肺癌的随访研究[J].重庆医学,2016,45(21):2929-2932.
[7]苏月华.吉非替尼和多西他赛+顺铂方案治疗老年晚期非小细胞肺癌的疗效比较[J].中国老年学杂志,2012,32(3):586-587.
[8]陈素梅,贾友超,焦顺昌.小细胞肺癌靶向治疗和免疫治疗的研究进展[J].武警医学,2016,27(9):957-960.
[9]Kaderbhai C,Richard C,Fumet J D,et al.Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer[J].Oncoimmunology,2017,6(9):1339.
[10]Matikas A,Ν.Kentepozidis,Ardavanis A,et al.Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients:a multicenter,phase IV study of the Hellenic Oncology Research Group(HORG)[J].Cancer Chemotherapy&Pharmacology,2016,78(2):1-8.
[11]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,(2):91-93.
[12]郭晓莺,申国宏,孙昌友,等.多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效及其不良反应[J].武警医学,2015,26(7):699-701.
[2]冯高华,陈晓峰.不同化疗方案治疗晚期非小细胞肺癌的疗效及对肿瘤标志物水平的影响[J].中国老年学杂志,2014,34(23):6601-6603.
[3]赵玉霞.吉西他滨联合顺铂对IIIB或IV期非小细胞肺癌的治疗效果[J].中国实用医刊,2017,44(1):87-88.
[4]太祥,陈满军,洪文娟,等.培美曲塞和紫杉醇分别联合奥沙利铂用于非小细胞肺癌术后辅助化学治疗疗效比较[J].重庆医学,2015,44(35):4936-4939.
[5]Bai M S,Wang X C,Luo L,et al.Clinical Efficacy of Aidi Injection Combined with DP Chemotherapy Regimen for Female Advanced Lung Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2016.
[6]李妮,邓泽虎,田福华,等.放射性125I粒子植入联合紫杉醇治疗非小细胞肺癌的随访研究[J].重庆医学,2016,45(21):2929-2932.
[7]苏月华.吉非替尼和多西他赛+顺铂方案治疗老年晚期非小细胞肺癌的疗效比较[J].中国老年学杂志,2012,32(3):586-587.
[8]陈素梅,贾友超,焦顺昌.小细胞肺癌靶向治疗和免疫治疗的研究进展[J].武警医学,2016,27(9):957-960.
[9]Kaderbhai C,Richard C,Fumet J D,et al.Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer[J].Oncoimmunology,2017,6(9):1339.
[10]Matikas A,Ν.Kentepozidis,Ardavanis A,et al.Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients:a multicenter,phase IV study of the Hellenic Oncology Research Group(HORG)[J].Cancer Chemotherapy&Pharmacology,2016,78(2):1-8.
[11]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,(2):91-93.
[12]郭晓莺,申国宏,孙昌友,等.多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效及其不良反应[J].武警医学,2015,26(7):699-701.